Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences Statistics

Total Valuation

XBIO has a market cap or net worth of $5.80 million. The enterprise value is $1.67 million.

Market Cap	5.80M
Enterprise Value	1.67M

Important Dates

The last earnings date was Thursday, November 13, 2025, before market open.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

XBIO has 2.29 million shares outstanding. The number of shares has increased by 0.11% in one year.

Current Share Class	2.29M
Shares Outstanding	2.29M
Shares Change (YoY)	+0.11%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.62%
Owned by Institutions (%)	2.97%
Float	1.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.36
Forward PS	8.24
PB Ratio	0.99
P/TBV Ratio	1.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.56

Current Ratio	4.56
Quick Ratio	3.71
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -57.43% and return on invested capital (ROIC) is -37.65%.

Return on Equity (ROE)	-57.43%
Return on Assets (ROA)	-31.56%
Return on Invested Capital (ROIC)	-37.65%
Return on Capital Employed (ROCE)	-83.68%
Revenue Per Employee	$1.43M
Profits Per Employee	-$1.58M
Employee Count	2
Asset Turnover	0.44
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.15% in the last 52 weeks. The beta is 2.41, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.41
52-Week Price Change	-44.15%
50-Day Moving Average	3.52
200-Day Moving Average	3.27
Relative Strength Index (RSI)	42.44
Average Volume (20 Days)	52,920

Short Selling Information

The latest short interest is 14,551, so 0.64% of the outstanding shares have been sold short.

Short Interest	14,551
Short Previous Month	22,549
Short % of Shares Out	0.64%
Short % of Float	0.73%
Short Ratio (days to cover)	0.15

Income Statement

In the last 12 months, XBIO had revenue of $2.86 million and -$3.16 million in losses. Loss per share was -$2.05.

Revenue	2.86M
Gross Profit	2.86M
Operating Income	-3.31M
Pretax Income	-3.16M
Net Income	-3.16M
EBITDA	n/a
EBIT	-3.31M
Loss Per Share	-$2.05

Balance Sheet

The company has $4.12 million in cash and n/a in debt, giving a net cash position of $4.12 million or $1.80 per share.

Cash & Cash Equivalents	4.12M
Total Debt	n/a
Net Cash	4.12M
Net Cash Per Share	$1.80
Equity (Book Value)	3.96M
Book Value Per Share	2.56
Working Capital	3.96M

Cash Flow

Operating Cash Flow	-2.72M
Capital Expenditures	n/a
Free Cash Flow	-2.72M
FCF Per Share	-$1.19

Margins

Gross margin is 100.00%, with operating and profit margins of -115.80% and -110.40%.

Gross Margin	100.00%
Operating Margin	-115.80%
Pretax Margin	-110.40%
Profit Margin	-110.40%
EBITDA Margin	n/a
EBIT Margin	-115.80%
FCF Margin	n/a

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.11%
Shareholder Yield	-0.11%
Earnings Yield	-54.45%
FCF Yield	-46.89%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

XBIO has an Altman Z-Score of -52.77 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-52.77
Piotroski F-Score	2